{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T06:54:31Z","timestamp":1776495271778,"version":"3.51.2"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"publisher","award":["21fk0310109"],"award-info":[{"award-number":["21fk0310109"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01AI144112"],"award-info":[{"award-number":["R01AI144112"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01AI146917"],"award-info":[{"award-number":["R01AI146917"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virus Research"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.virusres.2024.199451","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T21:48:58Z","timestamp":1724708938000},"page":"199451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Interferon alpha induces a stronger antiviral effect than interferon lambda in HBV\/HDV infected humanized mice"],"prefix":"10.1016","volume":"349","author":[{"given":"Sarah","family":"Duehren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6002-5213","authenticated-orcid":false,"given":"Takuro","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7591-8287","authenticated-orcid":false,"given":"Masataka","family":"Tsuge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Hiraga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan L.","family":"Uprichard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ohad","family":"Etzion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Glenn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theo","family":"Heller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott J.","family":"Cotler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Oka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Chayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harel","family":"Dahari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.virusres.2024.199451_bib0001","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/gutjnl-2020-322571","article-title":"Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5\/6 complex and silencing of the viral genome in vivo","volume":"71","author":"Allweiss","year":"2022","journal-title":"Gut"},{"issue":"Suppl. 1","key":"10.1016\/j.virusres.2024.199451_bib0002","first-page":"S579","article-title":"Mathematical modeling of HDV RNA, ALT and HBsAg kinetics suggests a dual mode of action of peginterferon lambda: the LIMT-1 Study","volume":"78","author":"Cardozo-Ojeda","year":"2023","journal-title":"Hepatology"},{"issue":"Suppl","key":"10.1016\/j.virusres.2024.199451_bib0003","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0168-8278(23)00451-8","article-title":"Week 48 results of the phase 3 D-LIVR study: a randomized double-blind, placebo-controlled trial, evaluating the safety and efficacy of lonafarnib-boosted with ritonavir with or without peginterferon alfa in patients with chronic hepatitis delta","volume":"78","author":"Etzion","year":"2023","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.virusres.2024.199451_bib0004","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1097\/HEP.0000000000000309","article-title":"Treatment of chronic hepatitis D with peginterferon lambda-the phase 2 LIMT-1 clinical trial","volume":"77","author":"Etzion","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.virusres.2024.199451_bib0005","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1055\/s-0032-1323628","article-title":"Clinical features of hepatitis D","volume":"32","author":"Farci","year":"2012","journal-title":"Semin. Liver. Dis."},{"issue":"1","key":"10.1016\/j.virusres.2024.199451_bib0006","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1038\/s41598-017-03946-9","article-title":"Both interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV\/HDV infected humanized mice","volume":"7","author":"Giersch","year":"2017","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.virusres.2024.199451_bib0007","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1002\/hep.27357","article-title":"Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling","volume":"60","author":"Guedj","year":"2014","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.virusres.2024.199451_bib0008","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/jmv.21525","article-title":"Evidence that methylation of hepatitis B virus covalently closed circular DNA in liver tissues of patients with chronic hepatitis B modulates HBV replication","volume":"81","author":"Guo","year":"2009","journal-title":"J. Med. Virol."},{"issue":"14","key":"10.1016\/j.virusres.2024.199451_bib0009","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00492-20","article-title":"Understanding Hepatitis B virus dynamics and the antiviral effect of interferon alpha treatment in humanized chimeric mice","volume":"95","author":"Reinharz","year":"2021","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/j.virusres.2024.199451_bib0010","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s11894-023-00901-9","article-title":"Hepatitis D virus and HBsAg dynamics in the era of new antiviral treatments","volume":"25","author":"Shekhtman","year":"2023","journal-title":"Curr. Gastroenterol. Rep."},{"issue":"3","key":"10.1016\/j.virusres.2024.199451_bib0011","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J. Hepatol."},{"issue":"9","key":"10.1016\/j.virusres.2024.199451_bib0012","doi-asserted-by":"crossref","first-page":"e00725","DOI":"10.1128\/AAC.00725-17","article-title":"Persistent loss of Hepatitis B virus markers in serum without cellular immunity by combination of peginterferon and entecavir therapy in humanized mice","volume":"61","author":"Uchida","year":"2017","journal-title":"Antimicrob. Agents Chemother"},{"issue":"3","key":"10.1016\/j.virusres.2024.199451_bib0013","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/HEP.0000000000000335","article-title":"HBV with precore and basal core promoter mutations exhibits a high replication phenotype and causes ER stress-mediated cell death in humanized liver chimeric mice","volume":"78","author":"Uchida","year":"2023","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.virusres.2024.199451_bib0014","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1099\/jgv.0.000726","article-title":"Usefulness of humanized cDNA-uPA\/SCID mice for the study of hepatitis B virus and hepatitis C virus virology","volume":"98","author":"Uchida","year":"2017","journal-title":"J. Gen. Virol."},{"issue":"2","key":"10.1016\/j.virusres.2024.199451_bib0015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2893.2007.00905.x","article-title":"Hepatitis B viral DNA is methylated in liver tissues","volume":"15","author":"Vivekanandan","year":"2008","journal-title":"J. Viral. Hepat."},{"key":"10.1016\/j.virusres.2024.199451_bib0016","series-title":"Hepatitis B. Key Facts. Vol. 2024","year":"2024"}],"container-title":["Virus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170224001448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170224001448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T22:50:02Z","timestamp":1726786202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168170224001448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":16,"alternative-id":["S0168170224001448"],"URL":"https:\/\/doi.org\/10.1016\/j.virusres.2024.199451","relation":{},"ISSN":["0168-1702"],"issn-type":[{"value":"0168-1702","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interferon alpha induces a stronger antiviral effect than interferon lambda in HBV\/HDV infected humanized mice","name":"articletitle","label":"Article Title"},{"value":"Virus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virusres.2024.199451","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"199451"}}